- This topic has 4 replies, 3 voices, and was last updated 9 years, 2 months ago by
.
-
I was wondering about this the other day when you posted the new Decision Support Tool.
i.e. For genotypes 2/4/5/6 is there any advantage when making a decision on treatment for the new Australian guidelines that recommend Peg/Riba with Sofosbuvir? Eg “if the patient has TT and maybe CT then follow EASL guidelines and prescribe Sof/Dac”
Or would using Sof with the Peg/Riba negate any advantage there?
G3a since ’78 – Dx ’12 – F4 (2xHCC)
24wk Tx – PEG/Riba/Dac 2013 relapsed
24wk Tx – Generic Sof/Dac/Riba 2015/16 relapsed
16wk Tx – 12/01/17 -> 03/05/17 NS3/NS5a + Generic Sof
SVR7 – 22/06/17 UND
SRV12 – 27/07/17 UND
SVR24 – 26/10/17 UND
Hmmm, on further reflection peg/riba is sub optimum for everyone regardless of their genes.
While it’s reasonably cost achievable to help our mums the best scenario is that PBS doesn’t end up discriminating against 9% of HCV infected people to save a few bucks.
Anyone know when the final rules get announced?
G3a since ’78 – Dx ’12 – F4 (2xHCC)
24wk Tx – PEG/Riba/Dac 2013 relapsed
24wk Tx – Generic Sof/Dac/Riba 2015/16 relapsed
16wk Tx – 12/01/17 -> 03/05/17 NS3/NS5a + Generic Sof
SVR7 – 22/06/17 UND
SRV12 – 27/07/17 UND
SVR24 – 26/10/17 UND
- You must be logged in to reply to this topic.